2025-523134-28-00招募中3 期
A national randomised multi-centre phase II/III trial using MesoPher in ABC borderline resectable pancreatic cancer (PREOPANC-6 trial)
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)5 个研究点 分布在 1 个国家目标入组 143 人开始时间: 2026年6月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 143
- 试验地点
- 5
研究概览
简要总结
Phase II: An improvement in the progression-free survival (PFS) per RECIST 1.1 of adjuvant dendritic cell therapy (MesoPher) in patients with ABC borderline resectable pancreatic cancer (exploratory) Phase III: To investigate the overall survival (OS) of MesoPher treatment.
研究设计
- 分配方式
- Randomized
- 主要目的
- Preopanc-6: Meso Pher In Abc Borderline Resectable Pancreatic Cancer
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •At registration: ABC borderline resectable pancreatic cancer, histologically or cytologically confirmed. ABC borderline is defined as resectable pancreatic cancer with a CA-19.9 level > 500 kU/L at diagnosis or borderline resectable pancreatic cancer. Resectability criteria are defined by the DPCG criteria.
- •Laboratory tests: ASAT/ALAT <5xULN (upper limit of normal), bilirubin <1.5xULN, Lactate dehydrogenase value < ULN and albumin value >
- •Women of childbearing potential (WOCB) must have a negative serum pregnancy test at screening. They must be willing to use an effective contraceptive method (intrauterine devices, hormonal contraceptives, contraceptive pill, implants, transdermal patches, hormonal vaginal devices, infusions with prolonged release) or true abstinence (when this is in line with the preferred and usual lifestyle*) during the study and for at least 12 months after the last study drug administration. *True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (such as calendar, ovulation, symptothermal, and post-ovulation methods) and withdrawal are not acceptable methods of contraception.
- •Men must be willing to use an effective contraceptive method (e.g. condom, vasectomy) during the study and for at least 12 months after the last study drug administration.
- •Ability to return to the hospital for adequate follow-up as required by this protocol.
- •Written informed consent according to ICH-GCP.
- •Inclusion and randomisation: Borderline resectable or resectable tumours according to the DPCG criteria. CA-19.9 levels of no more than 500 kU/L at the time of screening, and a valid reduction during neoadjuvant FOLFIRINOX according to the treating physician. Predefined exceptions apply for CA19-9 non-producers with PET-CT showing no metabolic progression, and for patients with CA19-9 levels above 500 kU/L who have demonstrated a valid reduction during FOLFIRINOX and are deemed clinically eligible by the treating physician, subject to approval after consultation with the central study team.
- •Patients must be at least 18 years old and be able to give written informed consent.
- •WHO performance status 0-
- •Patients must be able to undergo surgery.
- •Patients must have normal organ function and adequate bone marrow reserve: absolute neutrophil count > 1.0 x 109/l, total leucocyte count ≥ 3.0 x 109/l, platelet count > 100 x 109/l, renal function E-GFR ≥ 50 ml/min, and Hb > 6.0 mmol/l.
排除标准
- •At registration: a. Metastatic or locally advanced (unresectable) pancreatic cancer according to the DPCG criteria. b. Resectable pancreatic cancer with a CA19-9 < 500 kU/L at registration, unless predefined exception criteria (e.g. CA19-9 non-producer with PET-CT showing no distant metastases and no metabolic progression) are met and eligibility is confirmed by the central study team.
- •Has a known additional malignancy that is progressing or has required active treatment within the past two years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g., breast cancer, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
- •Has active autoimmune disease that has required systemic treatment in the past two years (i.e. with the use of disease-modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered systemic treatment and is allowed.
- •Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
- •Has an active infection requiring systemic therapy.
- •Has a known history of Human Immunodeficiency Virus (HIV) infection.
- •Has a known history of Hepatitis B (defined as Hepatitis B surface antigen or known active Hepatitis C virus infection.
- •Active or inadequately treated syphilis (Lues).
- •Has a history of current evidence of any condition, therapy or laboratory abnormality that might confound the results of the study, interfere with the participant’s participation for the entire duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study or within 12 months after the last administration of study treatment
- •At inclusion: Registered patients are excluded from randomisation if, during neoadjuvant FOLFIRINOX: a. they develop RECIST-defined progressive disease (see 11.3.2.3); or b. they fail to demonstrate a CA19-9 response compared with baseline values or have CA19-9 levels > 500 kU/L at screening, unless predefined exception criteria apply
- •Has had an allogeneic tissue/solid organ transplant.
- •Ampullary or distal bile duct cancer.
- •Severe concomitant systemic disorders that would compromise the safety of the patient or their ability to complete the study at the discretion of the investigator.
- •A WOCPB who has a positive urine pregnancy test at screening. A serum pregnancy test will be performed if the urine test cannot be confirmed as negative.
- •Current or previous use of autologous DC therapy or anti-tumour vaccinations.
- •A known allergy or hypersensitivity to the study drug or any study drug excipients.
- •History of life-threatening toxicity related to prior immune therapy that wasn’t manageable by the standard of care treatment.
- •Current use of steroids (or other immunosuppressive agents). Patients must have discontinued treatment for at least six weeks and not use such therapy during the study.
研究者
Study coordinator
Scientific
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
研究点 (5)
Loading locations...
相似试验
尚未招募
Unknown
Phase IV Multicentre Study on the Safety and Immunogenicity of Recombinant Hepatitis E Vaccine (E. coli) in Healthy AdultsCTRI/2025/12/099590Urihk Pharmaceutical Private Limited (Subsidiary of Ureka Hong Kong)1,000
招募中
2 期
Prospective study in patients with colon or rectum cancer with liver metastasis of the efficacy and toxicity of standard therapy (chemotherapy + targeted therapy) combined with immunotherapy and internal radiotherapy targeting the liver2024-517204-11-00Fondation Franc.Cancerologie Digestive52
进行中（未招募）
2 期
A clinical study to assess the safety and immunogenicity of liquid DTwP-rHepB-HIB-IPV vaccine when administered in healthy infants of 6-8 weeks.CTRI/2024/02/063223Ms Biological E Limited180
尚未招募
Unknown
To evaluate the safety effectiveness and Immune response of UstekiRel in 240 patients with Plaque Psoriasis, Psoriatic Arthritis, Ulcerative Colitis and Crohns DiseaseCTRI/2025/12/098446Reliance Life Sciences Pvt Ltd240
招募中
2 期
A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.Active Immunisation for Chikungunya Virus InfectionNCT07555392Bharat Biotech International Limited1,000